Cumulative Review of Hypertension in Patients with Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies Treated with Acalabrutinib

Join Dr Anecita Fadol (University of Texas MD Anderson Cancer Center, US), Dr Alessandra Ferrajoli (University of Texas, MD Anderson Cancer Center, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) as they provides an in-depth cumulative review of hypertension management in patients with Chronic Lymphocytic Leukemia (CLL) and other hematologic malignancies treated with Acalabrutinib. 

This webinar will explore the mechanisms, incidence and clinical implications of treatment-related hypertension, offering cardiologists evidence-based strategies to optimise cardiovascular care for this patient population. Don’t miss this opportunity to deepen your understanding and connect with fellow professionals in the field.

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.

This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.